iRegene Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- iRegene Therapeutics's estimated annual revenue is currently $930k per year.
- iRegene Therapeutics's estimated revenue per employee is $155,000
Employee Data
- iRegene Therapeutics has 6 Employees.
- iRegene Therapeutics grew their employee count by -14% last year.
iRegene Therapeutics's People
| Name | Title | Email/Phone |
|---|
iRegene Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.4M | 9 | 80% | N/A | N/A |
#2 | $1.6M | 10 | 0% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.4M | 9 | 29% | N/A | N/A |
#5 | $3.1M | 20 | -5% | $200M | N/A |
#6 | $0.8M | 5 | 25% | N/A | N/A |
#7 | $4.2M | 27 | -13% | $133M | N/A |
#8 | $0.9M | 6 | 20% | N/A | N/A |
#9 | $8.7M | 56 | 2% | $146M | N/A |
#10 | $2.8M | 18 | 20% | $93M | N/A |
What Is iRegene Therapeutics?
We research and develop proprietary chemically-derived allogeneic cell therapy for degenerative diseases like Parkinson’s Disease, Retinal Degenerative Diseases, Ischemic Stroke, etc. \n\nOur leading pipeline NouvNeu001 (Parkinson’s Disease) is scheduled to initiate Phase I clinical trial in 2023 H2.\n\nWe are a passionate team committed to developing first-in-class therapies for patients suffering from major incurable diseases. Making fast-acting and disease-reversing therapies accessible to patients in the greatest extent possible is our priority.
keywords:N/A
N/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Wuhan
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.7M | 14 | N/A | N/A |
#2 | $0.8M | 19 | N/A | N/A |
#3 | $3.9M | 62 | N/A | N/A |
#4 | $25M | 91 | 7% | N/A |
#5 | $33.9M | 96 | 10% | N/A |